| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5591452 | PURDUE PHARMA | Controlled release formulation |
May, 2014
(9 years ago) | |
| US6254887 | PURDUE PHARMA | Controlled release tramadol |
May, 2014
(9 years ago) | |
| US6607748 | PURDUE PHARMA | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
Jun, 2020
(3 years ago) | |
| US7988998 | PURDUE PHARMA | Sustained-release tramadol formulations with 24-hour efficacy |
Oct, 2023
(6 months ago) | |
Ryzolt is owned by Purdue Pharma.
Ryzolt contains Tramadol Hydrochloride.
Ryzolt has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Ryzolt are:
- US5591452
- US6254887
- US6607748
- US7988998
Ryzolt was authorised for market use on 30 December, 2008.
Ryzolt is available in tablet, extended release;oral dosage forms.
The generics of Ryzolt are possible to be released after 27 October, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 30, 2011 |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 30 December, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of RYZOLT before it's drug patent expiration?
More Information on Dosage
RYZOLT family patents
